טוען...
Mass spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: Comparison to IHC and FISH
BACKGROUND: Trastuzumab showed survival benefit for Her2-positive gastroesophageal cancers (GEC). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) currently determine eligibility for trastuzumab-based therapy. However, these low-throughput assays often produce discordant or e...
שמור ב:
הוצא לאור ב: | Gastric Cancer |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , |
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
2015
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4871781/ https://ncbi.nlm.nih.gov/pubmed/26581548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-015-0566-0 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|